文献速递临床试验与 GCP

ProMEDIC试验统计分析计划:预防性褪黑素用于重症监护谵妄

Statistical analysis plan for the Prophylactic Melatonin for Delirium in Intensive Care (ProMEDIC): a randomised controlled trial.
PubMed 文献 · Trials · 2021-01-05

本文报告多中心、随机、双盲、安慰剂对照试验ProMEDIC的统计分析计划(SAP),该试验已随机分配850例ICU患者(1:1)接受褪黑素或安慰剂,每日两次监测谵妄症状。SAP在数据库锁定和治疗分配揭盲前完成并提交发表,旨在避免因提前知晓结果而产生的偏倚,将用于确定预防性褪黑素能否降低ICU患者谵妄的发生率和严重程度。

要点

  • ProMEDIC试验已随机850例ICU患者,1:1接受褪黑素或安慰剂。
  • SAP在数据库锁定和揭盲前完成,以避免结果知晓偏倚。
  • 主要目标为确定预防性褪黑素能否降低ICU谵妄发生。

核心结论

  • 该SAP为ProMEDIC试验预先设定分析方案,以减少因提前知晓结果产生的偏倚,最终将判定预防性褪黑素能否降低ICU患者谵妄的发生率和严重程度。

研究设计与样本

  • ProMEDIC为多中心、随机、双盲、安慰剂对照试验,共随机850例ICU患者,按1:1分配接受褪黑素或安慰剂。
  • 参与者每日两次监测谵妄症状,SAP在数据库锁定和治疗分配揭盲前完成并提交发表。

主要发现

  • 本文及附加文件描述该试验的统计分析计划,包含将在主要和次要论文中报告的分析细节。

关键数值与推荐

  • 共850例ICU患者被随机(1:1)接受褪黑素或安慰剂。
  • 参与者每日两次监测谵妄症状。

临床怎么用

  • 该SAP为后续主要和次要分析提供预先设定的分析框架,避免结果知晓偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Delirium is defined as acute organic brain dysfunction characterised by inattention and disturbance of cognition. It is common in the intensive care unit and is associated with poorer outcomes. Good quality sleep is important in the prevention and management of delirium. Melatonin is a natural hormone secreted by the pineal gland which helps in the regulation of the sleep-wake cycle. It is possible that melatonin supplementation in intensive care improves sleep and prevents delirium. METHODS AND DESIGN: The 'Prophylactic Melatonin for Delirium in Intensive Care' study is a multi-centre, randomised, double-blinded, placebo-controlled trial. The primary objective of this study is to determine whether melatonin given prophylactically decreases delirium in critically ill patients. A total of 850 ICU patients have been randomised (1:1) to receive either melatonin or a placebo. Participants were monitored twice daily for symptoms of delirium. RESULTS: This paper and the attached additional files describe the statistical analysis plan (SAP) for the trial. The SAP has been developed and submitted for publication before the database has been locked and before the treatment allocation has been unblinded. The SAP contains details of analyses to be undertaken, which will be reported in the primary and secondary publications. DISCUSSION: The SAP details the analyses that will be done to avoid bias coming from knowledge of the results in advance. This trial will determine whether prophylactic melatonin administered to intensive care unit patients helps decrease the rate and the severity of delirium. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry (ANZCTR) ACTRN1261600043647 , registration date: 06 April 2016. WHO Trial Number - U1111-1175-1814.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wibrow B, Martinez FE, Ford A, et al. Statistical analysis plan for the Prophylactic Melatonin for Delirium in Intensive Care (ProMEDIC): a randomised controlled trial. Trials. 2021. PMID: 33402209. doi:10.1186/s13063-020-04981-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。